![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RPGRIP1L |
Gene summary for RPGRIP1L |
![]() |
Gene information | Species | Human | Gene symbol | RPGRIP1L | Gene ID | 23322 |
Gene name | RPGRIP1 like | |
Gene Alias | COACH3 | |
Cytomap | 16q12.2 | |
Gene Type | protein-coding | GO ID | GO:0001654 | UniProtAcc | Q68CZ1 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23322 | RPGRIP1L | male-WTA | Human | Thyroid | PTC | 2.09e-04 | 7.01e-02 | 0.1037 |
23322 | RPGRIP1L | PTC01 | Human | Thyroid | PTC | 3.41e-03 | 3.74e-02 | 0.1899 |
23322 | RPGRIP1L | PTC05 | Human | Thyroid | PTC | 4.71e-04 | 1.92e-01 | 0.2065 |
23322 | RPGRIP1L | PTC06 | Human | Thyroid | PTC | 9.75e-12 | 2.34e-01 | 0.2057 |
23322 | RPGRIP1L | PTC07 | Human | Thyroid | PTC | 1.52e-08 | 1.97e-01 | 0.2044 |
23322 | RPGRIP1L | ATC12 | Human | Thyroid | ATC | 2.80e-13 | 1.25e-01 | 0.34 |
23322 | RPGRIP1L | ATC13 | Human | Thyroid | ATC | 8.83e-15 | 1.45e-01 | 0.34 |
23322 | RPGRIP1L | ATC2 | Human | Thyroid | ATC | 4.42e-07 | 5.21e-01 | 0.34 |
23322 | RPGRIP1L | ATC4 | Human | Thyroid | ATC | 1.31e-10 | 1.76e-01 | 0.34 |
23322 | RPGRIP1L | ATC5 | Human | Thyroid | ATC | 2.29e-06 | 1.61e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0007163111 | Thyroid | PTC | establishment or maintenance of cell polarity | 115/5968 | 218/18723 | 1.15e-10 | 3.90e-09 | 115 |
GO:0001701111 | Thyroid | PTC | in utero embryonic development | 175/5968 | 367/18723 | 1.40e-10 | 4.73e-09 | 175 |
GO:0048732113 | Thyroid | PTC | gland development | 193/5968 | 436/18723 | 2.88e-08 | 6.42e-07 | 193 |
GO:0001889112 | Thyroid | PTC | liver development | 79/5968 | 147/18723 | 3.08e-08 | 6.82e-07 | 79 |
GO:0061008112 | Thyroid | PTC | hepaticobiliary system development | 80/5968 | 150/18723 | 3.94e-08 | 8.55e-07 | 80 |
GO:000182215 | Thyroid | PTC | kidney development | 133/5968 | 293/18723 | 7.57e-07 | 1.18e-05 | 133 |
GO:000165517 | Thyroid | PTC | urogenital system development | 149/5968 | 338/18723 | 1.41e-06 | 2.01e-05 | 149 |
GO:007200114 | Thyroid | PTC | renal system development | 135/5968 | 302/18723 | 1.76e-06 | 2.43e-05 | 135 |
GO:002191514 | Thyroid | PTC | neural tube development | 76/5968 | 152/18723 | 2.40e-06 | 3.17e-05 | 76 |
GO:006054115 | Thyroid | PTC | respiratory system development | 86/5968 | 203/18723 | 1.02e-03 | 6.08e-03 | 86 |
GO:00220382 | Thyroid | PTC | corpus callosum development | 10/5968 | 14/18723 | 2.77e-03 | 1.38e-02 | 10 |
GO:00215373 | Thyroid | PTC | telencephalon development | 100/5968 | 248/18723 | 2.90e-03 | 1.44e-02 | 100 |
GO:00309007 | Thyroid | PTC | forebrain development | 143/5968 | 379/18723 | 8.47e-03 | 3.56e-02 | 143 |
GO:00017389 | Thyroid | PTC | morphogenesis of a polarized epithelium | 41/5968 | 94/18723 | 1.10e-02 | 4.38e-02 | 41 |
GO:000716329 | Thyroid | ATC | establishment or maintenance of cell polarity | 122/6293 | 218/18723 | 8.46e-12 | 3.16e-10 | 122 |
GO:000170126 | Thyroid | ATC | in utero embryonic development | 183/6293 | 367/18723 | 6.62e-11 | 2.11e-09 | 183 |
GO:004873233 | Thyroid | ATC | gland development | 210/6293 | 436/18723 | 1.50e-10 | 4.59e-09 | 210 |
GO:000188927 | Thyroid | ATC | liver development | 85/6293 | 147/18723 | 1.37e-09 | 3.43e-08 | 85 |
GO:006100827 | Thyroid | ATC | hepaticobiliary system development | 86/6293 | 150/18723 | 1.96e-09 | 4.78e-08 | 86 |
GO:000182222 | Thyroid | ATC | kidney development | 146/6293 | 293/18723 | 5.81e-09 | 1.28e-07 | 146 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPGRIP1L | SNV | Missense_Mutation | c.3841G>A | p.Asp1281Asn | p.D1281N | Q68CZ1 | protein_coding | tolerated(0.1) | benign(0.063) | TCGA-97-A4M5-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
RPGRIP1L | SNV | Missense_Mutation | c.1331N>T | p.Arg444Leu | p.R444L | Q68CZ1 | protein_coding | deleterious(0.02) | benign(0.017) | TCGA-L9-A7SV-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | CR | |
RPGRIP1L | SNV | Missense_Mutation | novel | c.1164N>C | p.Gln388His | p.Q388H | Q68CZ1 | protein_coding | deleterious(0) | benign(0.081) | TCGA-MN-A4N4-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
RPGRIP1L | SNV | Missense_Mutation | c.3883N>G | p.Thr1295Ala | p.T1295A | Q68CZ1 | protein_coding | deleterious(0) | benign(0.079) | TCGA-22-4601-01 | Lung | lung squamous cell carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
RPGRIP1L | SNV | Missense_Mutation | novel | c.3778N>T | p.Val1260Phe | p.V1260F | Q68CZ1 | protein_coding | deleterious(0.03) | benign(0.304) | TCGA-43-2578-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RPGRIP1L | SNV | Missense_Mutation | novel | c.2113G>C | p.Glu705Gln | p.E705Q | Q68CZ1 | protein_coding | deleterious(0) | possibly_damaging(0.865) | TCGA-56-A5DR-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
RPGRIP1L | SNV | Missense_Mutation | c.663N>C | p.Gln221His | p.Q221H | Q68CZ1 | protein_coding | tolerated(0.22) | benign(0.017) | TCGA-60-2722-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | taxol | PD | |
RPGRIP1L | SNV | Missense_Mutation | c.3105N>C | p.Glu1035Asp | p.E1035D | Q68CZ1 | protein_coding | tolerated(0.08) | benign(0.003) | TCGA-66-2773-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
RPGRIP1L | SNV | Missense_Mutation | novel | c.2102N>T | p.His701Leu | p.H701L | Q68CZ1 | protein_coding | deleterious(0.01) | benign(0.308) | TCGA-68-7755-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Unspecific | SD | |
RPGRIP1L | SNV | Missense_Mutation | novel | c.550N>C | p.Asp184His | p.D184H | Q68CZ1 | protein_coding | deleterious(0.01) | benign(0.332) | TCGA-77-7141-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |